Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274568 · ClinicalTrials.gov registry record · Phase 1
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05274568 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 5 participants.
The verdict
NCT05274568, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to: Evaluate \[18F\]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with \[18F\]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory objectives are: * Determine the safety and tolerability of microdose \[18F\]UCB-2897 * Evaluate preliminary dosimetry of \[18F\]UCB-2897 Additional exploratory objectives are: * Determine the pharmacokinetics / metabolism of \[18F\]UCB-2897 * Determine the optimal imaging protocol for \[18F\]UCB-2897
Interventions
- DRUG [18F]UCB-2897
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2023-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05274568
The ClinicalTrials.gov registry entry for NCT05274568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]UCB-2897 is the first listed.
NCT05274568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05274568 about?
NCT05274568 is a clinical study titled "Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein". The overall goal of this protocol is to: Evaluate \[18F\]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with \[18F\]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory ob...
What is the current status of trial NCT05274568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-01-31. Estimated completion is 2023-10-25.
What interventions are being tested in trial NCT05274568?
The interventions under investigation include: [18F]UCB-2897 (DRUG).
Who is sponsoring clinical trial NCT05274568?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.